Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Tommy Mullaney"'
Autor:
Sunny Guin, Bobby K Liaw, Tomi Jun, Kristin Ayers, Bonny Patel, Timmy O'Connell, Matthew Deitz, Michael Klein, Tommy Mullaney, Tony Prentice, Scott Newman, Marc Fink, Xiang Zhou, Eric E Schadt, Rong Chen, William K Oh
Publikováno v:
PLoS ONE, Vol 17, Iss 8, p e0264800 (2022)
BackgroundUpfront docetaxel or novel hormonal agents (NHA) such as abiraterone and enzalutamide have become the standard of care for metastatic hormone sensitive prostate cancer (mHSPC). We evaluated real-world management of patients treated with the
Externí odkaz:
https://doaj.org/article/506615a56a514357b3ce831d397c5b43
Autor:
Whitney Jappe, Juan P. Wisnivesky, Eric E. Schadt, Tommy Mullaney, Tony Prentice, Scott B. Jones, Meng Ma, Xiang Zhou, Kristin L. Ayers, Rajwanth R. Veluswamy, Kyeryoung Lee, Fred R. Hirsch, Shuyu D. Li, Michelle Zimmerman, Howard Goldsweig, Li Li, Jane J. Liu, Scott Newman, Rong Chen, Arielle Redfern, Zongzhi Liu, Nicholas Hahner, Kamlesh K Yadav, William Oh, Matthew Dietz
Publikováno v:
The Oncologist
Background Racial disparities among clinical trial participants present a challenge to assess whether trial results can be generalized into patients representing diverse races and ethnicities. The objective of this study was to evaluate the impact of
Autor:
Tony Prentice, Sunny Guin, Scott Newman, Timmy O’Connell, William Oh, Tomi Jun, Kristin L. Ayers, Bobby K. Liaw, Marc Y. Fink, Bonny Patel, Matthew Deitz, Eric E. Schadt, Tommy Mullaney, Michael W. Klein, Rong Chen, Xiang Zhou
Background: Upfront docetaxel or novel hormonal agents (NHA) such as abiraterone and enzalutamide have become the standard of care for metastatic hormone sensitive prostate cancer (mHSPC). However, data comparing the efficacy of docetaxel and NHAs in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c94d5454e3dafb5b352608cfedb4c133
https://doi.org/10.21203/rs.3.rs-659032/v1
https://doi.org/10.21203/rs.3.rs-659032/v1
Autor:
Kyeryoung Lee, David Cohn, Zongzhi Liu, Lei Ai, Hunki Paek, Lan Jin, Kalpana Raja, Minghao Li, Xingmin Zhang, Tomi Jun, Mitchell Higashi, William Oh, Ediz S. Calay, Radoslav Savic, Krish Ghosh, Andrew Kasarskis, Tommy Mullaney, Qi Pan, Eric Schadt, Xiaoyan Wang
Publikováno v:
Journal of Clinical Oncology. 40:e13563-e13563
e13563 Background: Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease with multiple phenotypes and endotypes and associated with lung cancer development. In this study, we analyzed the clinical features of COPD including various
Autor:
Yun Mai, Zongzhi Liu, Christopher Gilman, Mingwei Zhang, Xiaoyan Wang, Kyeryoung Lee, Minghao Li, Qi Pan, Eric E. Schadt, Tommy Mullaney, Rong Chen, Meng Ma
Publikováno v:
Journal of Clinical Oncology. 39:e19512-e19512
e19512 Background: Targeted therapy is an important treatment for chronic lymphocytic leukemia (CLL). However, optimal strategies for deploying small molecule inhibitors or antibody therapies in the real world are not well understood, largely due to
Autor:
Mingwei Zhang, Xiaoyan Wang, Frank Makosiej, Christopher Gilman, Zongzhi Liu, Tony Prentice, Marc Y. Fink, Eric E. Schadt, Tommy Mullaney, Kyeryoung Lee, Yun Mai, Minghao Li, Zhiqiang Li, Qi Pan, Rong Chen, Meng Ma, Krish Ghosh
Publikováno v:
Journal of Clinical Oncology. 39:6592-6592
6592 Background: Clinical trial phenotyping is the process of extracting clinical features and patient characteristics from eligibility criteria. Phenotyping is a crucial step that precedes automated cohort identification from patient electronic heal
Autor:
Paul McDonagh, Tony Prentice, Minghao Li, Christopher Gilman, Arielle Redfern, Zongzhi Liu, Meng Ma, Yun Mai, Eric E. Schadt, Kyeryoung Lee, Qi Pan, Tommy Mullaney, Rong Chen, Mingwei Zhang, Xiaoyan Wang
Publikováno v:
Journal of Clinical Oncology. 39:e18747-e18747
e18747 Background: Accurate longitudinal cancer treatments are vital for establishing primary endpoints such as outcome as well as for the investigation of adverse events. However, many longitudinal therapeutic regimens are not well captured in struc
Autor:
Y. Li, Philip C. Mack, Marc Y. Fink, Tony Prentice, Kristin L. Ayers, Eric E. Schadt, Fred R. Hirsch, Scott Newman, Tommy Mullaney, Timmy O’Connell, Sunny Guin, W. Jappe, Z. Li, Michael I. Klein, Rong Chen, Y. Gong, Arielle Redfern, X. Zhou
Publikováno v:
Journal of Thoracic Oncology. 16:S423
Autor:
Dan Li, Rong Chen, Zongzhi Liu, Tony Prentice, Scott B. Jones, Xiaoyan Wang, Kyeryoung Lee, Christopher Gilman, Eric E. Schadt, Arielle Redfern, Tommy Mullaney, Yun Mai, Matthew Deitz, Xiang Zhou, Ying Ru, Meng Ma, Yunrou Gong
Publikováno v:
Journal of Clinical Oncology. 38:e14062-e14062
e14062 Background: Real world evidence generated from electronic health records (EHRs) is playing an increasing role in health care decisions. It has been recognized as an essential element to assess cancer outcomes in real-world settings. Automatica
Autor:
Scott Newman, Kyeryoung Lee, Li Li, Eric E. Schadt, Tommy Mullaney, Xiang Zhou, Rong Chen, Dan Li, Kristin L. Ayers, Whitney Jappe, Arielle Redfern, Michelle Zimmerman, William Oh, Zongzhi Liu, Meng Ma, Tony Prentice
Publikováno v:
Journal of Clinical Oncology. 38:e21514-e21514
e21514 Background: Although some advanced non-small cell lung cancer (aNSCLC) patients respond favorably to immune checkpoint inhibitors, a larger portion either do not respond or experience negative side effects. At present, there is no consensus on